Table 3.
Survival analysis: clinical characteristics and overall survival.
| Variable | Overall Survival | ||
|---|---|---|---|
| No. (%) | Median OS (95% CI)1 | p-value2 | |
| Age | <0.013 | ||
| <65 years | 167 (35) | 17.8 (12.4–23.2) | |
| ≥65 years | 312 (65) | 11.3 (8.9–13.7) | |
| Gender | <0.013 | ||
| Female | 312 (65) | 17.7 (13.8–21.7) | |
| Male | 167 (35) | 5.6 (3.7–7.6) | |
| Clinical subtype | <0.013 | ||
| Secondary AS† | 259 (54) | 20.6 (16.0–25.1) | |
| Primary AS | 169 (35) | 7.2 (5.1–9.4) | |
| Unknown | 51 (11) | 3.7 (0.0–8.8) | |
| Tumor size | 0.65 | ||
| ≤ 5 cm | 43 (9) | 16.8 (8.7–25.0) | |
| > 5 cm | 26 (5) | 13.1 (2.3–23.9) | |
| Unknown | 410 (86) | 12.6 (10.0–15.2) | |
| Tumor depth | <0.013 | ||
| Superficial | 134 (28) | 32.1 (14.5–49.9) | |
| Deep | 25 (5) | 2.8 (0.3–5.3) | |
| Unknown | 320 (67) | 9.6 (7.5–11.8) | |
| Distant metastases | <0.013 | ||
| No | 324 (68) | 20.8 (16.3–25.3) | |
| Yes | 79 (17) | 3.1 (2.0–4.1) | |
| Unknown | 76 (16) | 6.0 (3.3–8.6) | |
| Surgery | <0.013 | ||
| Yes | 306 (64) | 23.2 (16.4–30.1) | |
| No | 173 (36) | 4.0 (2.1–6.0) | |
| Radiation therapy | <0.013 | ||
| (Neo)adjuvant | 54 (11) | 26.1 (9.6–42.5) | |
| Primary | 41 (9) | 9.2 (5.4–13.1) | |
| No | 384 (80) | 12.6 (9.6–15.6) | |
| Chemotherapy | 0.28 | ||
| (Neo)adjuvant | 12 (3) | 13.7 (0.0–27.8) | |
| Primary | 47 (10) | 10.3 (6.5–14.2) | |
| No | 420 (88) | 12.8 (9.7–16.0) |
OS = overall survival, CI = confidence interval. †= RT, UV and Stewart Treves AS, 1 in months, 2 log-rank test, 3 p < 0.05.